Document:

TERMINATION OF LICENSE AND RESEARCH & DEVELOPMENT AGREEMENT

                        Dated the 28th of February, 2001

BETWEEN:

                          PRAXIS PHARMACEUTICALS, INC.,
                     a body corporate incorporated pursuant
                        to the laws of the State of Utah,
                       one of the United States of America
                             and having an office at
                 600 - 595 Hornby Street, Vancouver, BC, Canada
                                   ("Praxis")

                                     - and -

                 FAIRCHILD INTERNATIONAL INC., a body corporate
                      incorporated pursuant to the laws of
            the State of Nevada, one of the United States of America
                             and having an office at
                 600 - 595 Hornby Street, Vancouver, BC, Canada
                                  ("Fairchild")

Definitions:

"Field of Use" means arthritis and topical treatment of dermal wrinkles

"Net Revenue" means all consideration received by Praxis:

                  for the sale or other disposition of Licensed Products;

                  less the following:

                           (A)      all costs incurred by PRAXIS in the
                                    development of Licensed Products, including,
                                    without limitation, payments made by PRAXIS
                                    to external contractors, and expenses
                                    incurred by PRAXIS in connection with
                                    obtaining Regulatory Approvals;

                           (B)      all costs of direct materials, labour and
                                    overhead expenses required in the
                                    manufacture and production of Licensed
                                    Products;

                           (C)      costs incurred by PRAXIS in connection with
                                    the marketing, selling and distribution of
                                    Licensed Products;
<PAGE>

                           (D)      any tax or government charge (other than an
                                    income tax) levied on the sale,
                                    transportation or delivery of Licensed
                                    Product;

                           (E)      trade and quantity discounts or rebates
                                    actually allowed and taken; and

                           (F)      credits or allowances given or made for
                                    rejection or return of previously sold
                                    Licensed Products;

1.1      The parties entered into a License and Research & Development Agreement
         dated 11th May, 1999 ("License and R&D Agreement").

1.2      The parties have agreed to end the License and R&D Agreement by mutual
         agreement as allowed according to Section 18 of the License and R&D
         Agreement, with effect from the Commencement Date of this Agreement.

1.3      With effect from the Commencement Date of this Agreement:

         (a)  the parties agree that the Licence and R&D Agreement is
              terminated; and

         (b)  each party permanently releases each other party from any actions,
              suits, causes of action, arbitration, debts, dues, costs, claims,
              demands, verdicts and judgments, either at law or in equity or
              arising under statute ("Claims") which but for their entry into
              this termination, they or any of them have or may have against
              each other arising from or in connection with the early
              termination of the Licence and R&D Agreement.

1.4      Each party must:

         (a)  use its best efforts to do all things necessary or desirable to
              give full effect to this termination; and

         (b)  refrain from doing anything that might hinder performance of this
              termination.

1.5      As consideration for efforts made du ring the period of the License and
         R&D Agreement:

         (a)  The parties agree that Praxis Pharmaceuticals Inc. will retain
              those common shares of Fairchild Inc. assigned to Praxis under the
              terms of the License and R&D Agreement; and

<PAGE>

         (b)  Praxis will pay to Fairchild 30% of Net Revenues from sales of the
              agents in the field of use to a maximum of $250,000 over the first
              three years of sales.

         This Agreement shall enure to the benefit of and be binding upon the
parties hereto and their respective successors and permitted assigns.

         IN WITNESS WHEREOF the parties hereto have executed this Agreement as
of the day and year first above written.

                                        PRAXIS PHARMACEUTICALS, INC.

                                        Per: /S/ ROBERT SMART
                                            -----------------------------------

                                        Per:
                                            -----------------------------------

                                        FAIRCHILD INTERNATIONAL INC.

                                        Per: /S/ BYRON COX
                                            -----------------------------------

                                        Per:
                                            -----------------------------------TERMINATION OF LICENSE AND RESEARCH & DEVELOPMENT AGREEMENT

                        Dated the 28th of February, 2001

BETWEEN:

                          PRAXIS PHARMACEUTICALS, INC.,
                     a body corporate incorporated pursuant
                        to the laws of the State of Utah,
                       one of the United States of America
                             and having an office at
                 600 - 595 Hornby Street, Vancouver, BC, Canada
                                   ("Praxis")

                                     - and -

                 FAIRCHILD INTERNATIONAL INC., a body corporate
                      incorporated pursuant to the laws of
            the State of Nevada, one of the United States of America
                             and having an office at
                 600 - 595 Hornby Street, Vancouver, BC, Canada
                                  ("FAIRCHILD")

Definitions:

"Field of Use" means arthritis and topical treatment of dermal wrinkles

"Net Revenue" means all consideration received by Praxis:

          for the sale or other disposition of Licensed Products;

          less the following:

              (A)   all costs incurred by PRAXIS in the development of Licensed
                    Products, including, without limitation, payments made by
                    PRAXIS to external contractors, and expenses incurred by
                    PRAXIS in connection with obtaining Regulatory Approvals;

              (B)   all costs of direct materials, labour and overhead expenses
                    required in the manufacture and production of Licensed
                    Products;

              (C)   costs incurred by PRAXIS in connection with the marketing,
                    selling and distribution of Licensed Products;

<PAGE>

              (D)   any tax or government charge (other than an income tax)
                    levied on the sale, transportation or delivery of Licensed
                    Product;

              (E)   trade and quantity discounts or rebates actually allowed and
                    taken; and

              (F)   credits or allowances given or made for rejection or return
                    of previously sold Licensed Products;

1.1      The parties entered into a License and Research & Development Agreement
         dated 11th May, 1999 ("License and R&D Agreement").

1.2      The parties have agreed to end the License and R&D Agreement by mutual
         agreement as allowed according to Section 18 of the License and R&D
         Agreement, with effect from the Commencement Date of this Agreement.

1.3      With effect from the Commencement Date of this Agreement:

         (a)  the parties agree that the Licence and R&D Agreement is
              terminated; and

         (b)  each party permanently releases each other party from any actions,
              suits, causes of action, arbitration, debts, dues, costs, claims,
              demands, verdicts and judgments, either at law or in equity or
              arising under statute ("Claims") which but for their entry into
              this termination, they or any of them have or may have against
              each other arising from or in connection with the early
              termination of the Licence and R&D Agreement.

1.4      Each party must:

         (a)  use its best efforts to do all things necessary or desirable to
              give full effect to this termination; and

         (b)  refrain from doing anything that might hinder performance of this
              termination.

1.5      As consideration for efforts made during the period of the License and
         R&D Agreement:

         (a)  The parties agree that Praxis Pharmaceuticals Inc. will retain
              those common shares of Fairchild Inc. assigned to Praxis under the
              terms of the License and R&D Agreement; and

<PAGE>

         (b)  Praxis will pay to Fairchild 30% of Net Revenues from sales of the
              agents in the field of use to a maximum of $250,000 over the first
              three years of sales.

                  This  Agreement  shall  enure to the benefit of and be binding
upon the parties hereto and their respective successors and permitted assigns.

                  IN WITNESS  WHEREOF the  parties  hereto  have  executed  this
Agreement as of the day and year first above written.

                                        PRAXIS PHARMACEUTICALS, INC.

                                        Per:/S/ ROBERT SMART
                                            -----------------------------------

                                        Per:
                                            -----------------------------------

                                        FAIRCHILD INTERNATIONAL INC.

                                        Per:/S/ BYRON COX
                                            -----------------------------------

                                        Per:
                                            -----------------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00021-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00021-of-00352.parquet"}]]